Company intelligence / Profile preview
GenomIdea
Ibaraki-city, Osaka-fu, Japananges.co.jp ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
GenomIdea developed the GEN0101 platform—an HVJ-E-based immunotherapeutic agent—tested in early-phase trials for advanced melanoma and malignant pleural mesothelioma. The tuberculosis vaccine program targeting IL‑12 was discontinued. GEN0101 showed immune activation properties but did not advance to late-stage development as an independent company.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineBiologicGene therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
TSD JapanAnGes MG/AnGes Inc.
Beyond the preview
Go deeper on GenomIdea.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenomIdea.